Cipharm
Kilani Group has seized the opportunity by becoming the majority shareholder of CIPHARM in Côte d'Ivoire since 2020 to embark on the manufacture, marketing and promotion of medicinal products for human use delivered on prescription and professional medical advice. Large-scale commitment resulting in scientific, human and industrial investments.
CIPHARM also aims to expand its current product portfolio according to the trend of the target markets by offering quality products at competitive prices, and is open to partnerships in order to produce drugs under license.
CIPAHRM produces competitive drugs in compliance with pharmaceutical and WHO GMPs that meet market needs.
Kilani Group became the major shareholder of CIPHARM in Côte d'Ivoire since 2020 in order to embark on the manufacture, marketing and promotion of medicinal products for human use, delivered on prescription and professional medical advice. It is a large-scale commitment resulting in scientific, human and industrial investments.CIPHARM also aims to expand its current product portfolio according to the trend of the target markets by offering quality products at competitive prices, and is always open for partnerships in order to produce drugs under license.
CIPHARM produces competitive drugs in compliance with pharmaceutical and WHO GMPs that meet market needs.
CIPHARM operates in several regions of Africa through a well-chosen network of distributors, representative agencies and manufacturing plants.
Our development strategy is based primarily on the African continent with a presence in more than 12 countries and 359 MAs registered.
Products and therapeutic areas
Antigrippaux
Antihistaminiques
Ampoules injectables
Antalgiques antipyrétiques
Antidiarrhéiques
Manufacture and distribution of drugs
Our values
Our values shape our culture, build our reputation and are known and recognized by all our employees.
- Integrity
- Respect
- Responsibility
- Openness
- Passion
